Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

MGTS reported for 2023 by RAS

4/1/24 MGTS

Forward Energy reported for 2023 by RAS

4/1/24 TGKJ

Chelyabinsk Forging and Pressing Plant reported for 2023 according by RAS

4/1/24 CHKZ

KuibyshevAzot reported for 2023 according by RAS

4/1/24 KAZT

Arsagera reported for 2023 by RAS

4/1/24 ARSA

Ural Forge reported for 2023 by RAS

4/1/24 URKZ

DZRD reported for 2023 by RAS

4/1/24 DZRD

Abrau-Durso reported for 2023 by RAS

4/1/24 ABRD

Bank Kuznetsky reported for 2023 by RAS

4/1/24 KUZB

VSMPO-AVISMA partially reported for 2023 by RAS

4/1/24 VSMO